{"id":"W3010740851","doi":"10.1177/1758835920909091","title":"Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer","year":2020,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Cancer Foundation; Mount Sinai Hospital; Dr. H. Bliss Murphy Cancer Centre; BC Cancer Agency","funders":"","keywords":"Atezolizumab; Medicine; Metastatic breast cancer; Pembrolizumab; Oncology; Internal medicine; Hazard ratio; Triple-negative breast cancer; Breast cancer; Population; Chemotherapy; Placebo; Progression-free survival; Clinical trial; Cancer; Immunotherapy; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001046296,0.0005152082,0.003608119,0.0003784953,0.00003105072,0.00000682104,0.0002660201,0.0003753818,0.0003892004],"category_scores_gemma":[0.0002101661,0.0003688678,0.0003926262,0.0009398345,0.001212872,0.0001322649,0.0001303531,0.001419648,0.000002683095],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001030149,"about_ca_system_score_gemma":0.002428175,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001721389,"about_ca_topic_score_gemma":0.0002106698,"domain_scores_codex":[0.9956272,0.0007438915,0.001974218,0.0005993851,0.0005839043,0.0004714543],"domain_scores_gemma":[0.9975925,0.0009225386,0.0009650858,0.0002149099,0.00009021763,0.0002147608],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00150376,0.0005208394,0.0002053587,0.006517102,0.0004509643,0.0001451299,0.001073852,1.31694e-7,0.000009561583,0.00003923245,0.000003336061,0.9895307],"study_design_scores_gemma":[0.008233334,0.001548862,0.001305107,0.06308019,0.001273001,0.0006181372,0.0009503334,0.0001577631,0.00004091601,0.0006805588,0.9215772,0.0005345956],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001000326,0.9958026,0.00002017268,0.001254274,0.0005337702,0.002004617,0.00007969148,0.00002062447,0.0001842259],"genre_scores_gemma":[0.002564153,0.9960965,0.000252773,0.0002024796,0.0002051614,0.0005865021,0.00003246878,0.00005254876,0.000007436124],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9889961,"threshold_uncertainty_score":0.9998763,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02692938279819948,"score_gpt":0.4086304143515668,"score_spread":0.3817010315533673,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}